Rebucci et al. [24] demonstrated that the combination of cetuximab (EGFR antibody) with a PI3K inhibitor could be a good therapeutic option in PIK3CA-mutated HNSCC. The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.